Moe AA; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. MoPeD3694.

UCLA School of Medicine, Los Angeles, United States

BACKGROUND: PEP for nonoccupational exposures needs to be evaluated as an option for preventing HIV, but adherence issues may hinder research analyses of effectiveness. METHODS: A risk-reduction study was begun in Los Angeles in April 2001 and recruited 100 adults in 10 months. All subjects were offered AZT/3TC within 72 hours of exposure. Substance abuse history, risky behaviors, adherence and side effects were noted and risk-reduction counseling was given at every visit. ALT,AST, CBC, glucose and creatinine were drawn at baseline, Week 2 and Week 4. HIV, hepatitis B and C, and syphilis serology were drawn at baseline. Repeat HIV testing was done at Week 6, Week 12, and Week 26. Urine was obtained for cocaine, amphetamines, and opiates at every visit. RESULTS:95 subjects were men. 53 were White, 30 Latino, 9 Black, 5 Asian, 3 Other. Median age and years of education were 31.76 and 14.7 respectively. 63 self-reported as gay, 19 heterosexual, 9 bisexual, 9 unknown. 45 of 95 (47%) respondents were abusing drugs and/or alcohol at the time of HIV exposure. Most had multiple types of sexual exposures; 1 subject was an injection drug user. 30 subjects did not complete at least 2 follow-up visits; 3 were recent enrollees and the rest were lost to follow-up. 2 subjects were HIV+ at baseline. 7 subjects quit AZT/3TC; 6 because of intolerance and 1 for unknown reasons. 62 subjects attended at least 2 follow-up visits and were evaluable for study. 55 (89%) self-reported >90% adherence, corroborated by pill counts. 53 (85%) reported at least one side effect, usually nausea, headache, fatigue, or dizziness. No subject was removed from the study because of unexpected or Grade III/IV side effects. CONCLUSION: In subjects who attend follow-up visits, adherence to AZT/3TC was high for PEP, despite side effects and histories of drug alcohol abuse

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Adult
• Anti-HIV Agents
• Bisexuality
• Combivir
• Drug Combinations
• HIV
• HIV Infections
• HIV Seropositivity
• Hepatitis B
• Homosexuality
• Homosexuality, Male
• Humans
• Lamivudine
• Los Angeles
• Male
• Substance-Related Disorders
• Zidovudine
• therapy

Other ID:

• GWAIDS0019116

UI: 102256614

From Meeting Abstracts